Olympia Pharmaceuticals

• Pharmacy Profile Name: Olympia Pharmaceuticals (503B) / Olympia Pharmacy (503A)
• Website: olympiapharmacy.com
• Address: 6700 Conroy Road, Suite 155, Orlando, FL 32835
• Phone: 407-420-8208
• CEO: Dr. Mark Mikhael, PharmD
• Co-Founder: Stan Loomis
• Pharmacy Type: FDA-registered 503B outsourcing facility + affiliated 503A compounding pharmacy
• Accreditations: LegitScript certified; FDA-registered 503B (cGMP compliant)
• GLP-1 Compounding: Liraglutide (current); formerly semaglutide and tirzepatide during shortage era
• Licensed: 48 states (targeting all 50)

About the Pharmacy

Olympia Pharmaceuticals describes itself as the only outsourcing facility in Central Florida and the national leader in compounded medications, with more than 35 years of expertise. It is a family-owned operation led by two generations of pharmacists, with a team comprising pharmacy technicians, pharmacists, microbiologists, and engineers.

Olympia Pharmaceuticals is a 503B FDA-registered outsourcing facility, licensed to ship medications for office use nationwide. Its affiliated 503A pharmacy, Olympia Pharmacy, extends this service by providing prescription fulfillment — bringing 503B medications directly to patients through their healthcare providers.

Olympia has expanded significantly in recent years. A new facility, Wesley Pharmaceuticals, opened in May 2025 and was built for high-volume manufacturing. Olympia currently produces approximately 150,000 vials per week; Wesley is projected to push that to 450,000 vials weekly.

GLP-1 Compounding

Olympia was one of the more prominent 503B outsourcing facilities operating in the compounded GLP-1 market during the shortage era. According to the FDA’s outsourcing facility product report, Olympia was one of seven large facilities nationally making compounded tirzepatide at the time the FDA declared the Zepbound shortage over in March 2025.

Following the end of the shortage and the FDA’s enforcement deadlines, Olympia pivoted its GLP-1 strategy: with semaglutide and tirzepatide restricted for 503B production, Olympia launched liraglutide — the first FDA-approved GLP-1 — in two formulas as of June 2025. Liraglutide remains on the FDA shortage list as of early 2026, making compounding of this molecule legally available under current regulations.

Olympia’s website describes its compounded GLP-1 agonists as treatments designed to help regulate appetite, reduce caloric intake, and promote steady, sustainable weight management.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

Type of Pharmacy

As a 503B outsourcing facility, Olympia must comply with strict current good manufacturing practice (cGMP) guidelines — the same standards that pharmaceutical manufacturers follow. All compounded drugs at Olympia are compounded under the direct supervision of a licensed pharmacist, and all products are subject to FDA inspection.

FDA Form 483 — May 2024: An FDA inspection of Olympia’s Orlando facility issued a Form 483 in May 2024. The 483 cited failure to identify drug products compounded in the previous six months as required under Section 503B of the FD&C Act — specifically, products compounded were not identified in semi-annual reports from June 2023 and December 2023. This is a reporting compliance finding rather than a sterility or patient safety finding. No FDA Warning Letter for Olympia was found in public records as of March 2026.

Olympia states that quality is its top priority, with every product tested and vetted by a third-party lab to meet cGMP and FDA standards before release, and next business day shipping as its standard turnaround.

States Licensed In

Olympia is licensed in 48 states, with California and Mississippi identified as the next to be added, with a goal of all 50 states covered by year-end.

Telehealth Providers They Work With

Olympia operates primarily as a B2B supplier to independent pharmacies, physician offices, med spas, and telehealth platforms rather than maintaining named consumer-facing telehealth partnerships. The company notes that NAD and its weight management products pair well with telemedicine, with telehealth practices exploring many of its product areas including liraglutide, amino acids, and ED injections. Olympia is listed as a preferred vendor within the Independent Pharmacy Cooperative (IPC) Vendor Advantage Network. No specific named consumer telehealth platform partnerships were found in public records.

Pricing from Reviews

Olympia sells primarily through pharmacies and provider accounts rather than direct-to-patient retail. Consumer-facing pricing for GLP-1 products is not publicly listed. The pharmacy’s B2B model means pricing flows through the purchasing practice or pharmacy rather than appearing on Olympia’s own website.

Overall Reviews

Olympia Pharmaceuticals has 28 Trustpilot reviews, with customers consistently praising fast shipping — next-day delivery is a recurring theme — and knowledgeable, responsive customer service staff. Staff members including Joseph, Mike Tran, and Matt are named individually in positive reviews. Negative reviews reference occasional account processing and shipping issues, with management actively responding and resolving complaints on the platform.